Search
forResearch 10 of 214
- Baricitinib Achieved Complete/Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Baricitinib for the Treatment of Alopecia Areata
- Real-life effectiveness and safety of baricitinib in 17 Japanese patients with alopecia areata: a 60-week single center study
- 008 Stratifying alopecia areata systemic treatments: Tailored approaches to disease severity
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study
- Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →